Furthermore, exploring therapeutic interventions targeting the pathways associated with these genes, such as BRAF inhibitors for BRAF-mutant thyroid cancers, or epigenetic modulators for reversing the hypermethylation of tumor suppressor genes, may offer promising avenues for improving patient outcomes. The gene discussed is BRAF; the disease is thyroid gland carcinoma.